Immune checkpoints are regulatory pathways in the immune system that maintain self-tolerance and modulate the immune response. Cancer cells often exploit these checkpoints to avoid immune detection. Inhibiting immune checkpoints, such as PD-1 and CTLA-4, can enhance the immune system's ability to fight cancer. Checkpoint inhibitors, like nivolumab and ipilimumab, have revolutionized cancer therapy.
